Asthma is a chronic inflammatory airway disease resulting in airflow obstruction, which in
part can become irreversible to conventional therapies, defining the concept of airway …

abstract Biologics have been a key component of severe asthma treatment, and there are
currently biologics available that target IgE, IL-5, IL-4/IL-13, and TSLP. Randomized …

Background Omalizumab has demonstrated efficacy in clinical trials of patients with asthma,
but real-world data are needed. Objective To assess outcomes after omalizumab initiation in …

Background Assessment of clinical outcomes in the real-world corroborates findings from
randomized controlled trials (RCTs). Objective This meta-analysis evaluated real-world data …

Type 2-immunity represents the typical adaptive response to allergen exposure in atopic
individuals. It mainly involves Th2 cells and immunoglobulin E, as the main orchestrators of …

Omalizumab was the first, and for a long time the only available monoclonal antibody for the
add-on treatment of severe allergic asthma. In particular, omalizumab selectively targets …

Importance Omalizumab is indicated for the management of chronic idiopathic urticaria
(CIU)(also known as chronic spontaneous urticaria) in adolescents and adults with …

Patients with moderate-to-severe asthma may now be treated using a variety of monoclonal
antibodies that target key inflammatory cytokines involved in disease pathogenesis. Existing …

Allergies are typically endemic, complex and heterogeneous diseases with a high impact at
quality of life. Mechanistically, type 2 immune responses involving eosinophil and basophil …

abstract IgE and mast cells play a pivotal role in various allergic diseases, including asthma,
allergic rhinitis, and urticaria. Treatment with omalizumab, a monoclonal anti-IgE antibody …